SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Sam Barone, MD, of Nanoscope Therapeutics discusses efficacy and safety data for the company’s MCO-010 optogenetic therapy.
Barone summarized the findings of two clinical trials for MCO-010: The RESTORE trial, which is investigating the therapy for use as a retinitis pigmentosa treatment, and the STARLIGHT study, which is investigating MCO-010 for Stargardt disease.
“In situations when there is significant degeneration of photoreceptors but there are still intact inner retinal cells, optogenetics therapy